ERBB2 and cancer: Given the promising results of T-DXd in the clinical setting, several other trials were launched to test this ADC to treat other HER2-expressing cancers, such as gastric (NCT05034887 and NCT04989816), lung (NCT05246514 and NCT05048797), colorectal (NCT04744831), bladder, urothelial, or endometrial (NCT04639219 and NCT04482309).